HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ADC Therapeutics (NYSE:ADCT) and maintained a $9 price target on the stock.

April 15, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $9 price target for ADC Therapeutics.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst like Robert Burns from HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on ADC Therapeutics' stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to price movements.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100